Literature DB >> 1797098

Use of tryptophan in combination with other antidepressant treatments: a review.

S N Young1.   

Abstract

In four studies, all carried out more than 20 years ago, the combination of tryptophan plus a monoamine oxidase inhibitor was significantly better than tryptophan plus placebo in the treatment of depression. However, there is no evidence that tryptophan has any clinically significant effect on other treatments such as tricyclic antidepressants and ECT. Side effects of the combination of tryptophan and a monoamine oxidase inhibitors have limited the use of this combination. The risk of the serotonin syndrome is small, but it can occur. However, rapid cessation of tryptophan seems to avoid any long lasting adverse effects of the serotonin syndrome. In situations where enhancement of the therapeutic effect of monamine oxidase inhibitors outweighs the risk of adverse effects, the combination of tryptophan and a monoamine oxidase inhibitor is clinically useful. As the studies to date have looked at regular depressed patients, what is needed now is studies of this combination in therapy resistant depression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1797098      PMCID: PMC1188360     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  45 in total

1.  Tricyclic antidepressants and tryptophan in unipolar depression.

Authors:  D M Shaw; D A Macsweeney; R Hewland; A L Johnson
Journal:  Psychol Med       Date:  1975-08       Impact factor: 7.723

2.  Amino acid assignment to one of three blood-brain barrier amino acid carriers.

Authors:  W H Oldendorf; J Szabo
Journal:  Am J Physiol       Date:  1976-01

3.  Tryptophan in the treatment of depression.

Authors:  A Coppen; D M Shaw; B Herzberg; R Maggs
Journal:  Lancet       Date:  1967-12-02       Impact factor: 79.321

4.  Potentiation of a monoamine oxidase inhibitor by tryptophan.

Authors:  A H Glassman; S R Platman
Journal:  J Psychiatr Res       Date:  1969-12       Impact factor: 4.791

5.  Tryptophan and an MAOI (nialamide) in the treatment of depression. A double-blind study.

Authors:  J L Ayuso Gutierrez; J J Aliño
Journal:  Int Pharmacopsychiatry       Date:  1971

6.  5-hydroxyindole metabolism in rat brain. A study of intermediate metabolism using the technique of tryptophan loading. I. Methods.

Authors:  G W Ashcroft; D Eccleston; T B Crawford
Journal:  J Neurochem       Date:  1965-06       Impact factor: 5.372

7.  Effect of tryptophan administration on 5HIAA in cerebrospinal fluid in man.

Authors:  D Eccleston; G W Ashcroft; T B Crawford
Journal:  J Neurol Neurosurg Psychiatry       Date:  1970-04       Impact factor: 10.154

8.  Potentiation of the antidepressant action of clomipramine by tryptophan.

Authors:  J Walinder; A Skott; A Carlsson; A Nagy; R Bjorn-Erik
Journal:  Arch Gen Psychiatry       Date:  1976-11

9.  Addition of L-tryptophan to electroconvulsive treatment in endogenous depression. A double-blind study.

Authors:  C Kirkegaard; S E Møller; N Bjørum
Journal:  Acta Psychiatr Scand       Date:  1978-11       Impact factor: 6.392

10.  Evaluation of the combination of tryptophan and ECT in the treatment of depression. I. Clinical analysis.

Authors:  G D'Elia; J Lehmann; H Raotma
Journal:  Acta Psychiatr Scand       Date:  1977-10       Impact factor: 6.392

View more
  5 in total

Review 1.  Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review.

Authors:  G B Baker; R T Coutts; K F McKenna; R L Sherry-McKenna
Journal:  J Psychiatry Neurosci       Date:  1992-11       Impact factor: 6.186

2.  L-Tryptophan: Biochemical, nutritional and pharmacological aspects.

Authors:  E L Sainio; K Pulkki; S N Young
Journal:  Amino Acids       Date:  1996-03       Impact factor: 3.520

3.  Antidepressant failure: augmentation or substitution?

Authors:  R T Joffe; A J Levitt
Journal:  J Psychiatry Neurosci       Date:  1995-01       Impact factor: 6.186

Review 4.  TDO as a therapeutic target in brain diseases.

Authors:  Cheng-Peng Yu; Ze-Zheng Pan; Da-Ya Luo
Journal:  Metab Brain Dis       Date:  2016-04-13       Impact factor: 3.584

Review 5.  The Role of Tryptophan Metabolites in Neuropsychiatric Disorders.

Authors:  Majid Davidson; Niloufar Rashidi; Kulmira Nurgali; Vasso Apostolopoulos
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.